Following the completion of the DMC (Data Monitoring Committee) safety review, Infant Bacterial Therapeutics AB (publ) announced the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, the company have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review,and there are no objections to continue the study. The company expects recruitment to increase as company now again recruit in two strata.